No connection

Search Results

BRTX

BEARISH
$0.25 Live
BioRestorative Therapies, Inc. · NASDAQ
Target $8.0 (+3091.1%)
$0.19 52W Range $2.04

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 08, 2026
Market cap
$6.39M
P/E
N/A
ROE
-320.5%
Profit margin
N/A
Debt/Equity
0.12
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
60%
BRTX shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 1/9). Concerns include weak profitability or high valuation.

Key Strengths

Low debt with D/E ratio of 0.12

Key Risks

Weak financial trend (Piotroski F-Score: 1/9)
Declining revenue (-54.7%)
Weak ROE of -320.5%

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
32
Weak
Value
50
Future
35
Past
40
Health
35
Dividend
0
AI Verdict
BRTX shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 1/9). Concerns include weak profitability or high valuation.
Key drivers: Low debt with D/E ratio of 0.12, Weak financial trend (Piotroski F-Score: 1/9), Declining revenue (-54.7%)
Confidence
20%
Value
50/100

Rule-based valuation (P/E + Graham).

Positives
  • Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Future
35/100

Rule-based growth outlook.

Positives
  • Insufficient data for clear positives.
Watchpoints
  • Revenue is contracting.
Past
40/100

Historical performance + price trend: Shares moved -99.5% over 5Y and -85.2% over 1Y.

Positives
  • Insufficient data for clear positives.
Watchpoints
  • ROE only -320.5%.
Health
35/100

Balance sheet & liquidity (Z-Score: N/A).

Positives
  • Low D/E ratio (0.12).
Watchpoints
No urgent risks highlighted.
Dividend
0/100

Dividend policy fallback.

Positives
  • Insufficient data for clear positives.
Watchpoints
  • No regular dividend payments.

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$0.25
Analyst Target
$8.0
Upside/Downside
+3091.1%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for BRTX and closest competitors.

Updated 2026-04-07
BRT
BioRestorative Therapies, Inc.
Primary
5Y
-99.5%
3Y
-93.0%
1Y
-85.2%
6M
-84.5%
1M
+8.1%
1W
-7.9%
BIA
bioAffinity Technologies, Inc.
Peer
5Y
-99.5%
3Y
-98.4%
1Y
-92.9%
6M
-86.5%
1M
+9.8%
1W
-1.5%
CLG
CollPlant Biotechnologies Ltd.
Peer
5Y
-97.4%
3Y
-95.1%
1Y
-85.0%
6M
-83.7%
1M
-43.0%
1W
-33.0%
BMR
Biomerica, Inc.
Peer
5Y
-95.7%
3Y
-88.5%
1Y
-46.5%
6M
-34.3%
1M
-3.0%
1W
0.0%
ALU
Allurion Technologies Inc.
Peer
5Y
-99.8%
3Y
-99.8%
1Y
-84.6%
6M
-75.5%
1M
-69.7%
1W
-11.7%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-0.48
PEG Ratio
N/A
P/B Ratio
6.43
P/S Ratio
17.76
EV/Revenue
9.73
EV/EBITDA
-0.23
Market Cap
$6.39M

Profitability

Profit margins and return metrics

Profit Margin N/A
Operating Margin -19516.8%
Gross Margin 93.37%
ROE -320.47%
ROA -119.56%

Growth

Revenue and earnings growth rates

Revenue Growth -54.7%
Earnings Growth N/A
Q/Q Revenue Growth -54.73%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.12
Low debt
Current Ratio
0.84
Weak
Quick Ratio
0.8
Poor
Cash/Share
$0.12

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
91.7%
Op. Margin
-19516.8%
Net Margin
-16365.5%
Total Assets
$0.0B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
10.44x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
103%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-03-26
$-0.32
+13.5% surprise
2025-11-12
$-0.33
+13.2% surprise
2025-08-12
$-0.3
+26.8% surprise
2025-05-14
$-0.64
-100.0% surprise

Healthcare Sector Comparison

Comparing BRTX against 166 companies in the Healthcare sector (15 bullish, 53 neutral, 98 bearish)
Return on Equity (ROE)
-320.47%
This Stock
vs
-44.87%
Sector Avg
+614.2% (Excellent)
Debt to Equity
0.12
This Stock
vs
5.59
Sector Avg
-97.9% (Less Debt)
Revenue Growth
-54.7%
This Stock
vs
119.32%
Sector Avg
-145.8% (Slower)
Current Ratio
0.84
This Stock
vs
3.38
Sector Avg
-75.1% (Weaker)

Similar Companies

Peer comparison within the same industry

Past News Coverage

Recent headlines mentioning BRTX from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI
Markets
Profile